Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non Small Cell Lung
- Registration Number
- NCT00191256
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
- Histologically or cytologically confirmed non small cell lung cancer
- No prior chemotherapy or radiation for non small cell lung cancer
- No prior malignancy
Exclusion Criteria
- Pregnancy or breastfeeding
- Serious concomitant disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Pathological complete response rate, in previously untreated patients with clinical Stage I and II non-small cell lung cancer (NSCLC).
- Secondary Outcome Measures
Name Time Method Response rate, disease free survival,toxicities including pulmonary toxicity, operative mortality, and quality of life.
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇺🇸Chapel Hill, North Carolina, United States